Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(16):1162-1163; doi:10.1093/jnci/djj324
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tu, D.
Right arrow Articles by Goss, P. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tu, D.
Right arrow Articles by Goss, P. E.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

CORRESPONDENCE

RESPONSE

Dongsheng Tu, Joseph L. Pater, James N. Ingle, Paul E. Goss

Affiliations of authors: National Cancer Institute of Canada, Clinical Trials Group, Kingston, Ontario, Canada (DT, JLP); Mayo Clinic, Rochester, MN (JNI); The Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA (PEG)

Correspondence to: Paul E. Goss, MD, PhD, FRCPC, FRCP (UK), Massachusetts General Hospital Cancer Center, Cancer Center Administration, 55 Fruit Street, Cox Building, Suite 640, Boston, MA 02114 (e-mail: pgoss@partners.org).

The first 10% of the full text of this article appears below.

We appreciate Dr Vakaet's compliments relating to our NCIC CTG MA17 clinical trial and would like to respond to the questions he raises regarding our updated report (1). Vakaet notes the differences in the number . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
Luc Vakaet
J Natl Cancer Inst 2006 98: 1162. [Extract] [Full Text] [PDF]